Rare disease clinical trials in the start-up phase seemed to suffer the most from the coronavirus outbreak, even as the US Food and Drug Administration and other funders tried to help investigators navigate the pandemic with minimal upheaval.
The FDA Office of Orphan Products Development said 5 March during the agency’s Rare Disease Day conference that 79% of clinical trials and natural history studies supported by
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?